CARLSBAD, Calif.--(BUSINESS WIRE)--March 24, 2006--SD Pharmaceuticals Inc. (SDP) today announced that it has completed a battery of pre-clinical studies on its novel nano-emulsion formulation of paclitaxel. This formulation is designated SDP-013 and is a proprietary nano-emulsion that does not contain any immunogenic solubilizer or macromolecule carrier. The battery of studies showed equal or superior efficacy in a mouse model of human ovarian cancer (SK-OV-3 cell line), a very favorable toxicity profile and a lack of immunogenicity compared to the existing Taxol(TM) formulation. The studies were conducted by an independent contracting laboratory and indicate that the SDP-013 paclitaxel is equivalent to Taxol(TM) and free of the immunogenicity associated with it and other paclitaxel formulations.
